CRO in Russia, cultural insight, market overview, medical system, and more
In Russia the clinical trials are regulated by the Federal Law No. 61 (Chapter 7). Approval to start a clinical trial is issued by the Ministry of Healthcare. The ethical examination is done by the Ethics Council of the Ministry of Healthcare, who issues an opinion on the ethical possibility for the given trial.
The pharmaceutical industry, which involves the development, manufacturing, and marketing of medicines, is expanding actively in Russia and is projected to grow to 2.35 billion Russian rubles by 2023. One of the factors shaping the market is the government’s push for national security in medicine supply, outlined in the document “Pharma 2030 Strategy.” Another driving force of the industry is the evolution of online retail of medicines, legalized during the COVID-19 pandemic.
Both international and local pharmaceutical companies are established in Russia and launch various projects related to the production of new drugs and vaccines. Some recent trends have focused on introducing innovations and increasing the quality of and access to healthcare.
A few advantages of conducting the clinical trial in Russia:
– centralized healthcare system
– available patient pool, high recruitment rate and good selection of highly qualified research centers
– lower investigator grants costs
– highly educated and motivated medical staff trained in Good Clinical Practices (GCP).
These factors make Russia a great choice for conducting clinical research.
Public healthcare is free for all Russian citizens. The healthcare services are offered by the state, municipal (local) as well as private providers. Free healthcare is provided by the state from the Federal Compulsory Medical Insurance Fund (FOMS). Citizens can also choose private healthcare services.
Get the latest news about GCT and the projects we support in a monthly email. View the mailing archive